BioCryst Pharmaceuticals Inc

Financials

Cash from operating activities 137.22 M142.16 M161.85 M95.14 M52.02 M347.37 M 347.37 M Cash from investing activities 6.86 M15.8 M128.24 M131.5 M52.59 M13.69 M 13.69 M Cash from financing activities 302.7 M359.67 M88.03 M32.48 M5.76 M349.93 M 349.93 M Free cash flow 136.7 M139.77 M160.5 M92.97 M50.9 M344.9 M 344.9 M

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.

BCRX

Financials

BioCryst Pharmaceuticals Inc

Haberler

BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2025 Earnings Call Transcript

TD Cowen, Orladeyo büyümesi nedeniyle BioCryst hissesini Al tavsiyesiyle korudu

TD Cowen reiterates BioCryst Pharma stock Buy rating on Orladeyo growth

BioCryst Pharmaceuticals (BCRX) Q4 Earnings and Revenues Surpass Estimates

BioCryst full year 2025 slides: record profit, injectable expansion

BioCryst kazancı $1,08 ile beklentilere göre daha iyi, kâr ise beklentilere göre yüksek

BioCryst earnings beat by $1.08, revenue topped estimates

Harrow (HROW) Reports Next Week: Wall Street Expects Earnings Growth

BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: Should You Buy?

Evercore ISI, BioCryst Pharma hissesi için takibi "outperform" derecelendirmesiyle yeniden başlattı

Evercore ISI resumes BioCryst Pharma stock coverage with outperform rating

Strength Seen in Korro Bio, Inc. (KRRO): Can Its 13.9% Jump Turn into More Strength?